Amgen (AMGN) net income: $7.7B
Amgen reported a net income of $7.7B for the year ended Dec 31, 2025, up 88.5% from $4.1B a year earlier.
From Amgen's filings with the SEC · Read the filing · AMGN stock page
Amgen net income by year
#54 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $7.7B | +89% |
| Dec 31, 2024 | $4.1B | -39% |
| Dec 31, 2023 | $6.7B | +3% |
| Dec 31, 2022 | $6.6B | +11% |
| Dec 31, 2021 | $5.9B | – |
Net income of similar companies
Companies in the same industry as Amgen, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Gilead Sciences | $8.5B | Dec 31, 2025 |
| Amgen | $7.7B | Dec 31, 2025 |
| Biogen | $1.3B | Dec 31, 2025 |
| Exelixis | $783M | Jan 2, 2026 |
| Neurocrine Biosciences | $479M | Dec 31, 2025 |
| Novavax | $440M | Dec 31, 2025 |
| Qiagen | $425M | Dec 31, 2025 |
Questions and answers
What is Amgen's net income?
Amgen reported a net income of $7.7B for the year ended Dec 31, 2025, up 88.5% from $4.1B a year earlier.
Numbers as reported in Amgen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology